ProMIS Neurosciences Inc (PMN) FinancialsPMNFinancialProMIS Neurosciences Inc

In the context of the broader market, PMN competes directly with industry leaders such as NTHI and MXCT. With a market capitalization of $123.62M, it holds a significant position in the sector. When comparing efficiency, PMN's gross margin of N/A stands against NTHI's N/A and MXCT's 63.86%. Such benchmarking helps identify whether ProMIS Neurosciences Inc is trading at a premium or discount relative to its financial performance.

PMN has shown a significant increase in cash reserves, ending Q2 2026 with approximately $53.4 million, which supports ongoing operations and clinical trials. However, the company has faced substantial losses, with a net income loss of $11,729,656 in Q2 2026.